Literature DB >> 26186805

Survival and spirometry outcomes after lung transplantation from donors aged 70 years and older.

Wiebke Sommer1, Fabio Ius1, Jawad Salman1, Murat Avsar1, Igor Tudorache1, Christian Kühn1, Bettina Wiegmann1, Georg Marsch1, Tim Kaufeld1, Norman Zinne1, Thomas Fuehner2, Mark Greer2, Jens Gottlieb2, Dietmar Boethig3, Axel Haverich1, Tobias Welte2, Gregor Warnecke4.   

Abstract

BACKGROUND: Mediocre donation rates and increasing demand for lung transplantation leads transplant centers to consider extended-criteria donor lungs. Arguably, the largest remaining non-utilized lung donor segment is the elderly individual, already considered for visceral organ donation but not thoracic. So far, transplantation of donor lungs aged ≥ 70 years is rarely reported, and recipient outcomes are unknown. Accordingly, we report a single-center series of lung transplantations from donors aged ≥ 70 years and compare outcomes with contemporary lung transplantations from younger donors.
METHODS: All bilateral lung transplantations performed at our center between March 2011 and July 2014 were analyzed, and 2 cohorts were built according to lung donor age.
RESULTS: A total of 440 bilateral lung transplantations were performed from 413 donors aged <70 years, and 27 donors aged ≥70 years. Donor characteristics did not differ in sex, donor time on mechanical ventilation before retrieval, or donor partial pressure of arterial oxygen/fraction of inspired oxygen ratio. Older donors were significantly less often positive for smoking history (43.7% vs 14.8%, p = 0.003) or for abnormal bronchoscopy results (52.9% vs 15.8%, p = 0.002). Recipients receiving donor lungs aged <70 years were younger than those receiving older donor lungs ≥ 70 (49.8 [range, 35-58] vs 58 [range, 53-62] years, p < 0.0001). Underlying diagnoses did not differ significantly between the groups. Post-operative mechanical ventilation times (15 [range, 10-59] vs 27.5 [range, 10-75.8] hours), intensive care unit stays (3 [range, 1-5] vs 3 [range, 1-8] days), and total hospital lengths of stay (24 [range, 22-40.5] vs 24 [range, 22-40] days) of the recipients did not differ significantly between the two groups. The percentage predicted forced expiratory volume in 1 second was 86.5% ± 26.2% 12 months after transplantation of younger lungs vs 72.2% ± 23.8% (p = 0.01) after transplantation of older lungs. Differentiating the spirometry findings according to underlying diseases showed significantly lower forced expiratory volume in 1 second values after transplantation of donor lungs aged ≥70 only in idiopathic pulmonary fibrosis recipients but not in emphysema patients. Patient survival up to 36 months was not significantly different, with 1-year survival being 92.9% for younger vs 95.5% for older donor lungs.
CONCLUSION: Use of donor lungs aged ≥70 years for transplantation is safe, without compromising survival. However, spirometry findings after transplantation with donors ≥70 years indicate better functional outcomes in emphysema recipients than in idiopathic pulmonary fibrosis recipients.
Copyright © 2015 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  extended criteria donor; lung transplantation; marginal donor; old donor

Mesh:

Year:  2015        PMID: 26186805     DOI: 10.1016/j.healun.2015.06.002

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  8 in total

Review 1.  Evaluation and Management of the Potential Lung Donor.

Authors:  Andrew Courtwright; Edward Cantu
Journal:  Clin Chest Med       Date:  2017-08-31       Impact factor: 2.878

Review 2.  Lung transplantation in elderly patients.

Authors:  Andrew Courtwright; Edward Cantu
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

3.  Impact of extended-criteria donor lungs according to preoperative recipient status and age in lung transplantation.

Authors:  Jee Won Suh; Jin Gu Lee; Moo Suk Park; Song Yee Kim; Su Jin Jeong; Hyo Chae Paik
Journal:  Korean J Transplant       Date:  2020-09-30

Review 4.  Lung cancer: a rare indication for, but frequent complication after lung transplantation.

Authors:  Dirk Van Raemdonck; Robin Vos; Jonas Yserbyt; Herbert Decaluwe; Paul De Leyn; Geert M Verleden
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

5.  National Heart, Lung, and Blood Institute and American Association for Thoracic Surgery Workshop Report: Identifying collaborative clinical research priorities in lung transplantation.

Authors:  Michael S Mulligan; David Weill; R Duane Davis; Jason D Christie; Farhood Farjah; Jonathan P Singer; Matthew Hartwig; Pablo G Sanchez; Daniel Kreisel; Lorraine B Ware; Christian Bermudez; Ramsey R Hachem; Michael J Weyant; Cynthia Gries; Jeremiah W Awori Hayanga; Bartley P Griffith; Laurie D Snyder; Jonah Odim; J Matthew Craig; Neil R Aggarwal; Lora A Reineck
Journal:  J Thorac Cardiovasc Surg       Date:  2018-08-18       Impact factor: 5.209

6.  Underutilization of potential donors for lung transplantation at a tertiary care center in North India.

Authors:  Kuruswamy Thurai Prasad; Inderpaul Singh Sehgal; Sahajal Dhooria; Valliappan Muthu; Ritesh Agarwal; Digambar Behera; Ashutosh Nath Aggarwal
Journal:  Lung India       Date:  2019 Sep-Oct

7.  Impact of donor lung quality on post-transplant recipient outcome in the Lung Allocation Score era in Eurotransplant - a historical prospective study.

Authors:  Jacqueline M Smits; Jens Gottlieb; Erik Verschuuren; Patrick Evrard; Rogier Hoek; Christiane Knoop; György Lang; Johanna M Kwakkel-van Erp; Robin Vos; Geert Verleden; Benoit Rondelet; Daniel Hoefer; Frank Langer; Rene Schramm; Konrad Hoetzenecker; Diana van Kessel; Bart Luijk; Leonard Seghers; Tobias Deuse; Roland Buhl; Christian Witt; Agita Strelniece; Dave Green; Erwin de Vries; Guenter Laufer; Dirk Van Raemdonck
Journal:  Transpl Int       Date:  2020-02-13       Impact factor: 3.782

8.  White donor, younger donor and double lung transplant are associated with better survival in sarcoidosis patients.

Authors:  Oriana Salamo; Shiva Roghaee; Michael D Schweitzer; Alejandro Mantero; Shirin Shafazand; Michael Campos; Mehdi Mirsaeidi
Journal:  Sci Rep       Date:  2018-05-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.